Managed Healthcare Executive May 31, 2024
Breyanzi is a CAR T-cell therapy now approved for four subtypes of non-Hodgkin lymphoma.
The FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel) to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.
Mantle cell lymphoma is an aggressive, rare form of non-Hodgkin lymphoma (NHL), representing roughly 3% of all NHL cases. Mantle cell lymphoma occurs more frequently in older adults with an average age at diagnosis in the mid-60s. In mantle cell lymphoma, relapse after initial treatment is common.
“There have been few advances in the treatment of relapsed or refractory MCL, and prognosis worsens for patients after each subsequent...
Today's Sponsors
Today's Sponsor